Clinical Trials
159 trialsCAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Henan Cancer Hospital
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
The Central Hospital of Lishui City
REGISTURK-LUNG
Oncological Clinical Research Association, Turkey
VENEZO-LUNG
Instituto Oncológico Dr Rosell
ZORALCS
University Hospital, Antwerp
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
Fudan University
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Fundacion Oncosur
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Biocity Biopharmaceutics Co., Ltd.
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Second Affiliated Hospital of Zunyi Medical University
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
PAVE
Hellenic Cooperative Oncology Group
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Shanghai Yunying Medical Technology
Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study
The First Hospital of Jilin University
Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
PEER
LUNGevity Foundation
Examining Clinical Trial Participation for Small Cell Lung Cancer Patients
Power Life Sciences Inc.
STAD-1
National Cancer Institute, Naples
DRIVE
Hellenic Cooperative Oncology Group
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Beijing Chest Hospital
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
Sun Yat-sen University
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Andarix Pharmaceuticals
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
The First Affiliated Hospital of Bengbu Medical University
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Guangzhou University of Traditional Chinese Medicine
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Shanghai Henlius Biotech
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Jiangsu HengRui Medicine Co., Ltd.
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
Hasan Kalyoncu University
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Circulating EV Long RNA Profiles in SCLC
Fudan University
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
JenKem Technology Co., Ltd.
CAMERA
Henan Cancer Hospital
Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
ChineseAMS
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Advenchen Laboratories, LLC
Effect of Combination Therapy on SCLC After Initial Treatment Failure
First Affiliated Hospital of Harbin Medical University